12月16日 - ** 药物开发商Nektar Therapeutics NKTR.O股价盘前下跌6.8%至50美元
** 该公司称，其治疗斑秃的实验性药物rezpegaldesleukin在一项中期研究中险些达不到在统计学上显著减轻斑秃严重程度的主要目标
** 称在排除四名严重违反研究资格的患者后，两个治疗组都达到了主要目标的统计学意义
** 斑秃是一种自身免疫性疾病，人体免疫系统会攻击毛囊，导致头皮出现斑块状脱发
** 公司计划在 2026 年进入该药物的后期开发阶段
** 截至上一交易日收盘，公司股价已上涨两倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.